	US 12,343,332 B2
	Treatment of a bacterial vaginal infection
Sylwia Berdzik-Kalarus, Katowice (PL); and Daniel Sulikowski, Warsaw (PL)
Assigned to ADAMED PHARMA S.A., Czosnow (PL)
Filed by Adamed Pharma S.A., Czosnow (PL)
Filed on May 8, 2023, as Appl. No. 18/313,671.
Application 18/313,671 is a division of application No. 16/604,850, granted, now 11,684,608, previously published as PCT/EP2018/058508, filed on Apr. 3, 2018.
Claims priority of application No. 17461524 (EP), filed on Apr. 14, 2017.
Prior Publication US 2023/0270725 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/4178 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 9/20 (2006.01); A61K 31/4164 (2006.01); A61K 31/7048 (2006.01); A61P 15/02 (2006.01); A61P 31/04 (2006.01)

CPC A61K 31/4178 (2013.01) [A61K 9/0034 (2013.01); A61K 9/06 (2013.01); A61K 9/2018 (2013.01); A61K 31/4164 (2013.01); A61K 31/7048 (2013.01); A61P 15/02 (2018.01); A61P 31/04 (2018.01)]

20 Claims

1. A method of treating a vaginal bacterial infection in an infected woman comprising vaginally administering 1 mg to 300 mg per day of furazidin to the infected woman to thereby treat the vaginal bacterial infection, wherein the vaginal bacterial infection is caused by Gardnerella vaginalis or Atopobium vaginae or a combination of the two.